Am J Transplant, Volume 16, Suppl 3 Archives - Page 12 of 180 - ATC Abstracts

2016 American Transplant Congress
Ischemia Reperfusion Induced Murine Heart Transplant Rejection Is Complement Dependent.
N. Chun,¹ M. Zhang,² R. Fairchild,³ P. Heeger.¹
¹Medicine, Icahn School of Medicine at Mount Sinai, NY, NY; ²Anesthesia, SUNY Downstate, NY, NY; ³Immunology, Cleveland Clinic, Cleveland, OH.
Increased posttransplant ischemia reperfusion injury (IRI) prevents costimulatory blockade induced heart graft survival but mechanisms linking innate and adaptive immunity are poorly understood. Based on…
2016 American Transplant Congress
Acute Rejection in Non-Human Primates Treated with Belatacept Is Mediated by a Unique CD8 Memory Subset.
D. Mathews,¹ W. Wakwe,¹ M. Lowe,¹ C. Breeden,¹ F. Leopardi,¹ A. Farris,¹ M. Song,¹ E. Strobert,² J. Jenkins,² C. Larsen,¹ R. Townsend,³ A. Adams.¹
¹Emory Transplant Center, Emory University, Atlanta, GA; ²Yerkes National Primate Research Center, Atlanta, GA; ³Bristol Myers-Squibb Pharmaceutical Research Institute, Princeton, NJ.
Belatacept is a high affinity version of the fusion protein CTLA4-Ig that blocks CD28 mediated T cell costimulation, providing a more targeted/less toxic form of…
2016 American Transplant Congress
Risk Prediction of End-Stage Renal Disease in Living Kidney Donors.
A. Massie, E. Chow, D. Segev.
JHU, Baltimore.
Recent studies have shown inreased risk of end stage renal disease (ESRD) in living kidney donors compared to healthy nondonors. Donors must understand the risk…
2016 American Transplant Congress
Long-Term Death-Censored Graft Loss in the DeKAF Study.
A. Matas,¹ A. Fieberg,¹ R. Leduc,¹ F. Cosio,² R. Gaston,³ R. Mannon,³ M. Cecka,⁴ D. Rush,⁷ B. Kasiske,⁵ S. Gourishankar,⁶ J. Connett,¹ J. Grande.²
¹U of MN, Mpls, MN; ²Mayo, Rochester, MN; ³UAB, Birmingham, AB; ⁴UCLA, LA, CA; ⁵HCMC, Mpls, MN; ⁶U Alberta, Edmonton, AB, Canada; ⁷UMB, Winnipeg, MB, Canada.
The aim of the Deterioration of Kidney Allograft Function study (DeKAF) was to identify and assess the pathologies of troubled kidney grafts, that is, those…
2016 American Transplant Congress
Automated Web-Based Monitoring Identifies Significant Clinical Changes in Patients Awaiting Kidney Transplant.
H. Braun, M. Parente, R. Hirose, G. Roll.
Surgery, University of California-San Francisco, San Francisco, CA.
Intro: The accuracy and integrity of very large waiting lists are difficult to maintain over time. We implemented newly available information technology to increase access…
2016 American Transplant Congress
Cognitive Impairment in Kidney Transplant Recipients.
A. Gupta,¹ D. Johnson,¹ G. Chen,¹ D. Subramaniam,¹ T. Polshak,¹ T. Thomas,¹ T. Schmitt,¹ D. Ladner,² A. Yu,¹ J. Burns.¹
¹University of Kansas Medical Center, Kansas City, KS; ²Northwestern University, Chicago, IL.
Background: Cognitive impairment is highly prevalent in end stage renal disease. The prevalence of cognitive impairment after kidney transplantation and the factors associated with it…
2016 American Transplant Congress
Comparison of Clinical Outcomes of Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients.
X. Wen,¹ M. Casey,¹ A. Santos,¹ A. Hartzema,² K. Womer.¹
¹Department of Medicine, University of Florida, Gainesville, FL; ²Department of Pharmaceutical Outcomes and Policy, University of Florida, Gainesville, FL.
To examine the utilization and clinical outcomes of belatacept in the real clinical setting, a retrospective cohort study was conducted using SRTR data that compared…
2016 American Transplant Congress
U.S. Dialysis Facility Characteristics Associated with Racial Disparities in Access to the Kidney Deceased Donor Transplant Waiting List.
J. Gander, L. Plantinga, S. Paul, S. Pastan, R. Patzer.
Emory University, Atlanta.
BACKGROUND Dialysis facility characteristics have been significantly associated with variation in U.S. transplant rates but facility characteristics associated with disparities in access to the kidney…
2016 American Transplant Congress
An Improved Method for the Evaluation of Microvascular Inflammation in Renal Allograft Biopsies.
M. Rooney,¹ Z. Ping,² D. Samarapungavan,³ R. Hennigar.⁴
¹Incyte Diagnostics, Spokane Valley, WA; ²Pathology, Beaumont Hospitals, Royal Oak, MI; ³Nephrology, Beaumont Hospitals, Royal Oak, MI; ⁴Nephropathology Associates, Little Rock, AR.
Background: Microvascular inflammation (MVI), assessed as glomerulitis (g) + peritubular capillaritis (ptc), is associated with T cell mediated (CMR) and antibody mediated (AMR) allograft rejection.…
2016 American Transplant Congress
Antibody Mediated Rejection and Mixed Acute Rejection: Long Term Results and Predictive Factors for Graft Loss Following Proteasome Inhibitor Therapy.
A. Lichvar,¹ A. Leino,¹ S. Tremblay,¹ B. Abu-Jawdeh,¹ A. Govil,¹ G. Mogilishetty,¹ M. Cardi,² J. Kremer,² M. Cuffy,^1,2 F. Paterno,¹ A. Shields,^1,2 D. Witte,¹ R. Alloway,¹ E. Woodle.¹
¹U of Cincinnati, Cincinnati; ²The Christ Hospital, Cincinnati.
Purpose: Proteasome inhibitor (PI) therapy has been increasingly used to treated antibody mediated rejection (AMR) and mixed acute rejection (MAR). The purpose of this study…